Product image of Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin Sandoz

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin)

Linagliptin and Metformin Hydrochloride, the active ingredient in Linagliptin/Metformin Sandoz, is a DPP‑4 inhibitor; biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise.
GNH India supplies Linagliptin/Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin Sandoz is used in the treatment of type 2 diabetes and related glycaemic control pathways.

  • Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect.
  • Patients requiring combination therapy: offers a fixed‑dose option to simplify regimens.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), raising endogenous incretin levels (GLP‑1, GIP) that enhance glucose‑dependent insulin secretion and suppress glucagon release. Metformin hydrochloride reduces hepatic gluconeogenesis, increases peripheral insulin sensitivity, and promotes glucose uptake, together lowering blood glucose concentrations.

Side Effects

The following adverse reactions have been reported with Linagliptin/Metformin therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhoea: loose stools often occurring early in treatment.
  • Abdominal discomfort: cramping or pain in the stomach area.
  • Headache: transient mild headache.
  • Dizziness: occasional light‑headedness.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Pancreatitis: severe inflammation of the pancreas.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or liver injury.
  • Renal impairment: worsening kidney function, especially in predisposed patients.

Precautions & Warnings

Before prescribing Linagliptin/Metformin, clinicians should consider several safety aspects.

  • Renal function: assess baseline creatinine clearance and monitor regularly.
  • Hepatic function: evaluate liver enzymes due to risk of lactic acidosis.
  • Cardiovascular disease: use with caution in patients with unstable heart conditions.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Drug interactions: review concomitant medications, especially insulin, sulfonylureas, and contrast agents.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin/Metformin may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Intravenous iodinated contrast: discontinue metformin before and after the procedure to prevent renal dysfunction.
  • Severe renal impairment: metformin accumulation can lead to lactic acidosis.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors or ARBs: monitor renal function and electrolytes.
  • Beta‑blockers: may mask symptoms of hypoglycaemia.
  • Alcohol consumption: can increase the risk of lactic acidosis.

Frequently Asked Questions

Linagliptin/Metformin Sandoz is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus when diet, exercise, and monotherapy with metformin are insufficient. It combines a DPP‑4 inhibitor with a biguanide to target different pathways of glucose regulation.

Linagliptin blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release and reduce glucagon. Metformin lowers hepatic glucose production and enhances insulin sensitivity in muscle and fat tissue. Together they provide complementary mechanisms to lower plasma glucose.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and prior therapy. The prescriber will select the appropriate strength and frequency according to individual needs.

Safety data for Linagliptin/Metformin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, the linagliptin/metformin combo has a lower intrinsic risk of hypoglycaemia and does not cause weight gain. Unlike some newer GLP‑1 receptor agonists, it is an oral fixed‑dose tablet, which may improve adherence for patients preferring pills over injections.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain stability throughout the shelf life.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing instructions provided by their healthcare professional.

The most critical safety concerns include lactic acidosis, especially in patients with renal impairment, and severe pancreatitis. Prompt medical attention is required if patients experience unexplained abdominal pain, rapid breathing, or signs of severe metabolic disturbance.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis should avoid this medication. Clinicians must also exercise caution in individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT